Clinical significance of immunocytochemistry for PIK3CA as a carcinogenesis-related marker on liquid-based cytology in cervical intraepithelial neoplasia

Oncology Reports

Volumn 15, Issue 2, 2006, Pages 387-391

  Goto, Tomoko ^a   Takano, Masashi ^b   Sasa, Hidenori ^b   Tsuda, Hitoshi ^b   Yamauchi, Kazuhiro ^c   Kikuchi, Yoshihiro ^b  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^c Biomedical Laboratories   (Japan)

Author keywords

Cervical intraepithelial neoplasia; Immunocytochemistry; Liquid based cytology; PIK3CA

Indexed keywords

KI 67 ANTIGEN; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN; PROTEIN P16INK4A; TUMOR MARKER;

ARTICLE; COMPARATIVE STUDY; CYTOLOGY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MASS SCREENING; METABOLISM; PAPILLOMA VIRUS; POLYMERASE CHAIN REACTION; ROC CURVE; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX TUMOR; VAGINA SMEAR; VIRUS INFECTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; CERVICAL INTRAEPITHELIAL NEOPLASIA; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYTOLOGICAL TECHNIQUES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MASS SCREENING; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 33744458773     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.15.2.387     Document Type: Article

References (27)

1. Bemstein SJ, Sanchez-Ramos L and Ndubisi B: Liquid-based cervical cytologic smear study and conventional Papanicolaou smears: a metaanalysis of prospective studies comparing cytologic diagnosis and sample adequacy. Am J Obstet Gynecol 185: 308-317, 2001. (Pubitemid 32769428)
2. Zur Hausen H: Advances in Viral Oncology. Vol. 8. Raven, New York, pp1-26, 1989.
3. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, Schiffman MH, Moreno V, Kurman R and Shah KV: Prevalence of human papillomavirus in cervical cancer: a world-wide perspective. International Biological Study on Cervical Cancer (IBSCC) Study Group. J Natl Cancer Inst 87: 796-802, 1995.
4. Miller AB: Natural history of cervical human papillomavirus infections. Lancet 357: 1816, 2001.
5. Bibbo M, Klump WJ, De Cecco J and Kovatich AJ: Procedure for immunocytochemical detection of P16INK4A antigen in thin-layer, liquid-based specimens. Acta Cytol 46: 25-29, 2002. (Pubitemid 34111420)
6. Saqi A, Pasha TL, McGrath CM, Yu GH, Zhang P and Gupta P: Overexpression of p16INK4A in liquid-based specimens (SurePath) as marker of cervical dysplasia and neoplasia. Diagn Cytopathol 27: 365-370, 2002. (Pubitemid 35424172)
7. Murphy N, Ring M, Killalea AG, Uhlmann V, O'Donovan M, Mulcahy F, Turner M, McGuinness E, Griffin M, Martin C, Sheils O and O'Leary JJ: p16INK4a as a marker for cervical dyskaryosis: CIN and cGIN in cervical biopsies and ThinPrep smears. J Clin Pathol 56: 56-63, 2003. (Pubitemid 36132476)
8. Sahebali S, Depuydt CE, Segers K, Vereecken AJ, van Marck E and Bogers JJ: Ki-67 immunocytochemistry in liquid based cervical cytology: useful as an adjunctive tool? J Clin Pathol 56: 681-686, 2003. (Pubitemid 37094128)
9. Sahebali S, Depuydt CE, Segers K, Moeneclaey LM, Vereecken AJ, van Marck E and Bogers JJ: P16INK4a as an adjunct marker in liquid-based cervical cytology. Int J Cancer 108: 871-876, 2004. (Pubitemid 38112616)
10. Brown DC and Gatter KC: Ki67 protein: the immaculate deception? Histopathology 40: 2-11, 2002. (Pubitemid 34107377)
11. Hildesheim A, Schiffman MH, Gravitt PE, Glass AG, Greer CE, Zhang T, Scott DR, Rush BB, Lawler P, Sherman ME, Hurman RJ and Manos MM: Persistence of type-specific human papillomavirus infection among cytologically normal women. J Infect Dis 169: 235-240, 1994. (Pubitemid 24045578)
12. Zur Hausen H: Disrupted dichotomous intracellular control of human papillomavirus infection in cancer of the cervix. Lancet 343: 955-957, 1994.
13. Rameh LE and Cantley LC: The role of phosphoinositide 3-kinase lipid products in cell function. J Biol Chem 274: 8347-8350, 1999. (Pubitemid 29164617)
14. Tlsty TD: A molecular blueprint for targeting cancer? Nat Genet 21: 64-65, 1999.
15. Shayesteh L, Lu Y, Kuo WL, Baldocchi R, Godfrey T, Collins C, Pinkel D, Powell B, Mills GB and Gray JW: PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 21: 99-102, 1999. (Pubitemid 29036292)
16. Ma YY, Wei SJ, Lin YC, Lung JC, Chang TC, Whang-Peng J, Liu JM, Yang DM, Yang WK and Shen CY: PIK3CA as an oncogene in cervical cancer. Oncogene 19: 2739-2744, 2000. (Pubitemid 30339223)
17. Redon R, Muller D, Caulee K, Wanherdrick K, Abecassis J and Du Manoir S: A simple specific pattern of chromosomal aberrations at early stages of head and neck squamous cell carcinomas: PIK3CA but not p63 gene as a likely target of 3q26-qter gains. Cancer Res 15: 4122-4129, 2001. (Pubitemid 32720980)
18. Zhang A, Maner S, Betz R, Angstrom T, Stendahl U, Bergman F, Zetterberg A and Wallin KL: Genetic alterations in cervical carcinomas: frequent low-level amplifications of oncogenes are associated with human papillomavirus infection. Int J Cancer 101: 427-433, 2002.
19. Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, Raab S, Sherman M, Wilbur D, Wright T Jr and Young N: The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 287: 2114-2119, 2002. (Pubitemid 34437346)
20. Yoshikawa H, Kawana T, Kitagawa K, Mizuno M, Yoshikura H and Iwamoto A: Detection and typing of multiple genital human papillomaviruses by DNA amplification with consensus primers. Jpn J Cancer Res 82: 524-531, 1991.
21. Ho GY, Bierman R, Beardsley L, Chang CJ and Burk RD: Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 338: 423-428, 1998. (Pubitemid 28135669)
22. Schiffman MH, Bauer HM, Hoover RN, et al: Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst 85: 958-964, 1993. (Pubitemid 23177581)
23. The Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesions Triage Study (ALTS) Group: Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized trial. J Natl Cncer Inst 92: 397-402, 2000.
24. Castle PE, Wacholder S, Lorincz AT, Scott DR, Sherman ME, Glass AG, Rush BB, Schussler JE and Schiffman M: A prospective study of high-grade cervical neoplasia risk among human papillomavirus-infected women. J Natl Cancer Inst 94: 1406-1414, 2002. (Pubitemid 35154145)
25. Castle PE, Wacholder S, Sherman ME, Lorincz AT, Glass AG, Scott DR, Rush BB, Demuth F and Schiffman M: Absolute risk of a subsequent abnormal pap among oncogenic human papillomavirus DNA-positive cytologically negative women. Cancer 95: 2145-2151, 2002. (Pubitemid 35253376)
26. Woenckhaus J, Steger K, Werner E, Fenic I, Gamerdinger U, Dreyer T and Stahl U: Genomic gain of PIK3CA and increased expression of p110alpha are associated with progression of dysplasia into invasive squamous cell carcinoma. J Pathol 198: 335-342, 2002. (Pubitemid 35277384)
27. Heselmeyer K, Schrock E, Du Manoir S, Blegen H, Shah K, Steinbeck R, Auer G and Ried T: Gain of chromosome 3q defines the transition from severe dysplasia to invasive carcinoma of the uteine cervix. Proc Natl Acad Sci USA 93: 479-484, 1996. (Pubitemid 26038181)